CASE CCC ANNUAL RETREAT
Call for Abstracts: Poster Competition
All graduate students, postdocs and fellows conducting cancer research are invited to submit abstracts for poster presentations at the retreat, the evening of July 11. Judges will review abstracts based on the relationship to cancer, novelty, significance of findings, and clarity. Monetary prizes will be awarded! More information is available on the Cancer Center website. The deadline to submit abstracts to email@example.com is Friday, June 27 at 5 pm.
The 2014 Case CCC Annual Scientific Retreat is fast approaching! The evening of Thursday, July 10 will be held at the Wolstein Research Building and will feature a keynote address by Kevin Shannon, MD from UCSF, on Preclinical Models to Test Strategies for Targeting Oncogenic Ras. A cocktail reception with heavy hors d'oeuvres will follow, allowing you the chance to network with your colleagues. New this year, there will be discussion of new members and their research, including new member poster presentations during the reception.
The retreat will continue Friday, July 11 at Corporate College East. We have a full scientific line-up of talks from Cancer Center members: Emerging Topics and Trends; Cancer Signaling and Drug Resistance; Cancer Genomics & Population Sciences; Experimental Therapeutics; Highlight on Innovative Awards.
A mid-day breakout for each scientific program to discuss new initiatives, collaborations, and requests for Cancer Center support through research pilot project and core resources will be one of the highlights of the day.
Finally, we will once again have poster presentations by students, postdocs and fellows. Poster judging will run concurrently with the cocktail reception. This is your chance to view the incredible research being conducted by the next generation of cancer researchers. Please encourage your trainees, fellows and students to submit an abstract by the June 27 deadline.
CASE CCC IN THE NEWS
Biotech Startup Developing Prostate Cancer Treatment is Raising $7.5M
Med City News - June 18, 2014
A biotechnology startup that spun out of University Hospitals of Cleveland last year has raised its first big round of financing since its launch two years ago. Dual Therapeutics (co-founded by Case Comprehensive Cancer Center member Dr. Goutham Narla), which is developing therapeutics for prostate cancer, lung cancer and acute lymphoblastic leukemia, is raising $7.5 million, according to an amended Form D filed with the U.S. Securities and Exchange Commission.
Most Breast Cancer Patients Not Exercising Enough; Local, National Studies Target Black Women
The Plain Dealer - June 17, 2014
A small pilot study in Cleveland, and a much larger national study, have reached similar conclusions about black women who have been treated for breast cancer: They're likely not getting enough crucial exercise that could help with staying healthy and avoiding a cancer recurrence..."There's emerging evidence that exercise may be beneficial for breast cancer survivors in terms of lowering the risk of a recurrence, and for survival," said Case Comprehensive Cancer Center member Dr. Cynthia Owusu, an oncologist at University Hospitals Case Medical Center and one of the study investigators...Owusu and colleagues from Case Western Reserve University, the Cleveland Clinic and MetroHealth Medical Center teamed up with the staff at the Beachwood location of The Gathering Place, a non-profit cancer support organization. They designed a study in which black women would take part in 20 weeks of exercise in a group setting along with a support group and independent walking. All of the women had either completed treatment or were within a year of doing so.
Tony Gwynn's Cancer: How Smokeless Tobacco Can Contribute to Disease
Fox News - June 17, 2014
"Chewing tobacco, specifically snuff, actually has [compounds] that rough up the mucous [membrane]; this is meant to aid the absorption of nicotine, but it also creates a more permeable place for carcinogens to enter the tissue,"Dr. Chad Zender, in the otolaryngology department at UH Case Medical Center and member of the Case Comprehensive Cancer Center, told FoxNews.com. "And just like tobacco smoke, tobacco itself has cancer-causing compounds in it. If you add it to things like alcohol, it works together synergistically."
A Way Forward in Genomic Medicine
ASCO Post - June 10, 2014
Over the past several decades, the convergence of scientific discovery, technology, and therapeutic developments has created an unparalleled opportunity to integrate our growing knowledge of genomics into the clinical practice of oncology. To shed light on the current state and future of genomics-driven cancer medicine, The ASCO Post recently spoke with Charis Eng, MD, PhD, FACP, ACS Clinical Research Professor, Chair and founding Director of the Genomic Medicine Institute at the Cleveland Clinic's Lerner Research Institute, and member of the Case Comprehensive Cancer Center.
Radiation in Conjunction with Chemotherapy Delivers Promising New Treatment Options for Patients with Low-grade Gliomas
Helio/HemOnc Today - June 9, 2014
Manmeet Ahluwalia, MD, of the brain tumor and neuro-oncology center at Cleveland Clinic and member of the Case Comprehensive Cancer Center, offers his point-of-view on the presentation on treatment options for patients with low-grade gliomas presented at the ASCO Annual Meeting. Standard of care for these patients is typically radiation alone; new data presented showed the benefit of utilizing a new upfront therapy which included radiation in conjunction with chemotherapy.
Exemestane Provides New Treatment Option for Premenopausal Women with Hormone-sensitive Breast Cancer
Helio/HemOnc Today - June 7, 2014
Jame Abraham, MD, FACP, director of the Breast Cancer Program at the Cleveland Clinic Taussig Cancer Institute and member of the Case Comprehensive Cancer Center, reviews the results of two phase 3 trials, TEXT and SOFT. According to study results, exemestane more effectively prevented breast cancer recurrences than tamoxifen, when given with ovarian function suppression, in premenopausal women with hormone-sensitive cancers.
Dale R. Shepard, MD, PhD, FACP, Highlights Future of Developmental Therapeutics
Helio/HemOnc Today - May 31, 2014
In this video, Dale R. Shepard, MD, PhD, FACP, staff physician in the Department of Hematology/Oncology at Cleveland Clinic and member of the Case Comprehensive Cancer Center, discusses the exciting progress and ongoing considerations associated with new drug development. According to Shepard, researchers are currently focusing on combination treatments that utilize new and previously established signaling agents, as well as the combination of signaling agents and immunotherapy.
Prognostic and Predictive Factors in Castrate-resistant Prostate Cancer
Med Page Today - June 2014
Eric Klein, MD, Chairman, Cleveland Clinic Glickman Urological and Kidney Institute and member of the Case Comprehensive Cancer Center, discusses prognostic and predictive factors in castrate-resistant prostate cancer.
Focus on Science June 2014
AACR-Women in Cancer Research (WICR)- June 2014
Written by Case Comprehensive Cancer Center member,Charis Eng, MD, PhD, Chair and founding Director of the Genomic Medicine Institute at the Cleveland Clinic's Lerner Research Institute. "The optimal manner of achieving seamless and effective translational cancer research is on a single platform of research, clinical care and education. On such a platform, the broad thrust of my laboratory can be characterized as clinical cancer genetics translational research, which involves the utilization of nucleic acid-based technologies to identify, characterize, and understand genes which cause susceptibility to traditional and complex heritable cancer syndromes, to determine their role in sporadic carcinogenesis and to perform molecular epidemiologic analyses as they might relate to clinical applications, namely cancer risk assessment, genetic counseling, and gene-informed clinical management...
Transplant Readmission Predicts Decreased Survival
Clinical Oncology - June 2014
Early readmission after hematopoietic stem cell transplant (HSCT) predicts lower five-year overall survival (OS), according to a large retrospective review. The relative risk appears to be slightly higher in those who received reduced-intensity conditioning (RIC), but OS was significantly lower for both RIC and myeloablative regimens if a readmission occurred within 30 days of discharge after HSCT...Navneet Majhail, MD, the director of the Blood and Marrow Transplant Program at the Taussig Cancer Institute at the Cleveland Clinic and member of the Case Comprehensive Cancer Center in Ohio, said he was not surprised by the association between early readmission and decreased long-term survival. "Most readmissions occur for infections, GVHD and relapse, and these events account for the majority of post-transplant mortality, and their occurrence frequently portends a poor prognosis for patients," Dr. Majhail said. He believed, however, that the data suggested potential opportunities to improve care.
RESEARCH HIGHLIGHTS/MEMBER NEWS
Newly Discovered Protein Inhibits Cancer Growth
Cleveland Clinic researchers have discovered a protein that inhibits the growth of cancerous tumors and slows development of new blood vessels that help cancers to spread. A research team led by Paul Fox, PhD, of the Department of Cellular and Molecular Medicine in Cleveland Clinic's Lerner Research Institute and member of the Case Comprehensive Cancer Center, discovered that a variant of VEGF-A decreases angiogenesis. The researchers named the variant VEGF-Ax. The protein cuts off the blood supply to tumors and inhibits tumor development in animal models. The research has the potential to pave the way for further scientific inquiry, Dr. Fox says. "This research is significant because it will open new avenues of angiogenesis and cancer research," Dr. Fox says.
Daly and Meropol Receive NCI Grant to Improve Communication With Patients about Clinical Trials
Barbara J. Daly, PhD, RN, FAAN, the CWRU Gertrude Perkins Oliva Professor in Oncology Nursing, and Neal J. Meropol, MD, Case CCC Associate Director for Clinical Research, received a grant from the National Cancer Institute, National Institutes of Health for their study, Oncology Nurse IMPACT: Improving Communication with Patients about Clinical Trials.
Khalil Awarded Grant from March of Dimes
Ahmad Khalil, PhD, Assistant Professor of Genetics and Genome Sciences at CWRU, received funding from a March of Dimes Cell Lineage and Differentiation Research Grant for his study, Epigenetic regulation of spermatogenesis by lincRNAs. Insights gained from the study could have implications for human health, including birth defects as well as cancer biology.
Limited Submission: Gabrielle's Angel Foundation
Gabrielle's Angel Foundation has invited the Case CCC to submit two applications (1 conventional and 1 integrative) for its annual Medical Research Awards. Eligible candidates must have their MD or PhD degree and currently hold a junior faculty position at a 501(c)(3) teaching research institution. Applicants must also currently be an Assistant Professor, hold a tenure track position, and have spent no more than five years in their current position.
Interested candidates should submit a one-page LOI to Kristin Waite (firstname.lastname@example.org) by Wednesday, June 25, 2014.
Internal LOI Deadline: June 25
External Application Deadline: August 15
American Society of Cytopathology
The American Society of Cytopathology is accepting applications for the ASC Foundation Patient Advocacy Grant, available to ASC members, patient advocacy groups and neighboring societies. This annual award is for ongoing or new projects for advocacy efforts for patients with gynecologic and other cancers, or to educate patients on the need for effective screening programs. Topics for the grant should support ongoing or new projects for advocacy efforts for patients with gynecologic and/or other cancers.
Deadline: August 15
Center for Global Health Short-Term Scientist Exchange Program
Short-Term Scientist Exchange Program (STSEP) promotes collaborative research between established U.S. and foreign scientists from low, middle, and upper-middle income countries by supporting, in part, exchange visits of cancer researchers between U.S. and foreign laboratories. The visits vary in duration.
Candidates must have a PhD, MD or a certified equivalent degree, a minimum of one year postdoctoral experience in cancer research, and an invitation from a qualified host. Persons holding U.S. permanent resident status ("green card") or a work visa are not eligible for this program. Awardees must fulfill the visa requirements of the host country. Awards are limited to visits of six months or less, and cannot be renewed or extended. Shorter visits are given preference.
Deadline: September 1, December 1, and March 1, June 1
2014 AICR Conference Scholarship
The 2014 AICR Annual Research Conference will be held October 29-31, 2014. This conference will feature an exciting program which will explore current topics in food, nutrition, physical activity and cancer. A limited number of scholarships for registration and conference hotel accommodations will be available for doctoral students in nutrition and cancer who are studying in the United States. Scholarship applicants are required to submit a poster abstract with their scholarship application and scholarship recipients are required to present a poster for the conference.
Deadline: September 5
Case Comprehensive Cancer Center Protocol Review and Monitoring Committee Reminder
The Protocol Review and Monitoring Committee (PRMC) must review and approve any amendment to a cancer study prior to IRB review and approval when the following study information is changed: Objective and/or end-points; Eligibility criteria; Treatment and/or dosing; Biostatistical analysis; and Biospecimen collection and processing. These requirements apply to cancer studies using any Institutional Review Board, including but not limited to the University Hospitals IRB, Cleveland Clinic IRB, and Chesapeake IRB. Please contact April Firstencel, PRMC Manager, (216.286.2294; email@example.com) with any questions.
MARK YOUR CALENDARS
NCRM Cancer Stem Cell Conference
The first CWRU: National Center for Regenerative Medicine Cancer Stem Cell Conference will be held in Cleveland,August 17-20, 2014. This conference is guaranteed to have incredible research from a variety of backgrounds in the Cancer Stem Cell field, and will feature keynote speakers from over 25 different institutions from around the world.
PREVIOUSLY ANNOUNCED OPPORTUNITIES
NIH BULLETIN – Notices and Funding Opportunities
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.